NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
Sellas Life Sciences faces high risk in the Phase 3 REGAL AML trial for GPS. Click here to know why I rate the SLS stock a ...
An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. Researchers at Baylor College of Medicine, University of Veterinary ...
SENTI-202 targets CD33 or FLT3, sparing EMCN, enhancing precision in treating hematologic malignancies like AML. Preliminary data shows high efficacy, with significant composite complete remission ...
Chromosomal instability plays a crucial role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer ...
Senti Biosciences, Inc. announced progress in its Phase 1 clinical trial of SENTI-202 for treating Acute Myeloid Leukemia (AML), a disease that affects approximately 20,800 newly diagnosed patients in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results